Recent Progress in the Diagnosis and Management of Type 2 Diabetes Mellitus in the Era of COVID-19 and Single Cell Multi-Omics Technologies
Type 2 diabetes mellitus (T2DM) is one of the world’s leading causes of death and life-threatening conditions. Therefore, we review the complex vicious circle of causes responsible for T2DM and risk factors such as the western diet, obesity, genetic predisposition, environmental factors, and SARS-Co...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | LIFE-BASEL
12 No. 8 |
| Tárgyszavak: | |
| doi: | 10.3390/life12081205 |
| mtmt: | 33056290 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/24930 |
| LEADER | 02136nab a2200289 i 4500 | ||
|---|---|---|---|
| 001 | publ24930 | ||
| 005 | 20220822121208.0 | ||
| 008 | 220822s2022 hu o 0|| Angol d | ||
| 022 | |a 2075-1729 | ||
| 024 | 7 | |a 10.3390/life12081205 |2 doi | |
| 024 | 7 | |a 33056290 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Kupai Krisztina | |
| 245 | 1 | 0 | |a Recent Progress in the Diagnosis and Management of Type 2 Diabetes Mellitus in the Era of COVID-19 and Single Cell Multi-Omics Technologies |h [elektronikus dokumentum] / |c Kupai Krisztina |
| 260 | |c 2022 | ||
| 300 | |a Terjedelem: 25 p.-Azonosító: 1205 | ||
| 490 | 0 | |a LIFE-BASEL |v 12 No. 8 | |
| 520 | 3 | |a Type 2 diabetes mellitus (T2DM) is one of the world’s leading causes of death and life-threatening conditions. Therefore, we review the complex vicious circle of causes responsible for T2DM and risk factors such as the western diet, obesity, genetic predisposition, environmental factors, and SARS-CoV-2 infection. The prevalence and economic burden of T2DM on societal and healthcare systems are dissected. Recent progress on the diagnosis and clinical management of T2DM, including both non-pharmacological and latest pharmacological treatment regimens, are summarized. The treatment of T2DM is becoming more complex as new medications are approved. This review is focused on the non-insulin treatments of T2DM to reach optimal therapy beyond glycemic management. We review experimental and clinical findings of SARS-CoV-2 risks that are attributable to T2DM patients. Finally, we shed light on the recent single-cell-based technologies and multi-omics approaches that have reached breakthroughs in the understanding of the pathomechanism of T2DM. | |
| 650 | 4 | |a Endokrinológia és anyagcserebetegségek (benne cukorbetegség, hormonok) | |
| 700 | 0 | 1 | |a Várkonyi Tamás |e aut |
| 700 | 0 | 1 | |a Török Szilvia |e aut |
| 700 | 0 | 1 | |a Gáti Viktória |e aut |
| 700 | 0 | 1 | |a Czimmerer Zsolt |e aut |
| 700 | 0 | 1 | |a Puskás László |e aut |
| 700 | 0 | 1 | |a Szebeni Gábor |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/24930/1/KupaiKlife-12-01205.pdf |z Dokumentum-elérés |